VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.

By D. Bates, T. Cui, J. M. Doughty, M. Winkler, M. Sugiono, J. Shields, D. Peat, D. Gillatt, S. Harper. Cancer Research, 2002

607 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease (2005, background): “Recently, another splice variant of human VEGF-A was identified, VEGF-A165b, which lacks exon 6 and contains an alternative exon 8 encoding a novel carboxy-terminal sequence, thereby raising the possibility of the existence of a family of sister isoforms containing this novel carboxyl terminus [21].”
VEGF in Signaling and Disease: Beyond Discovery and Development (2019, background): “Several inhibitory isoforms of VEGF have also been recently described, including VEGF165b (Bates et al., 2002) and VEGFAx (Eswarappa et al.”